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Abstract
Idiopathic Pulmonary Fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias. It is typically associated with extensive and progressive fibrosis, is fatal and
has limited treatment options. Characteristically IPF patients display large lymphocyte
aggregates composed of CD3+ T cells and CD20+ B cells within the lung tissue that are
located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a
range of host antigens, suggesting a breakdown in immunological tolerance. In this review
we examine the role of T and B cells in IPF pathogenesis and discuss how loss of selftolerance to lung specific proteins could exacerbate disease progression in IPF. We discuss
what these results mean in terms of future prospects for immunotherapy of IPF.
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Introduction
Interstitial lung diseases (ILDs) are a heterogeneous group of lung disorders. There are many
type of ILDs which recently have been reclassified into three broad categories; 1) Chronic
fibrosing interstitial pneumonia (including idiopathic pulmonary fibrosis (IPF)), 2) Smoking
related interstitial pneumonia (respiratory bronchiolitis-interstitial lung disease and
desquamative interstitial pneumonia) and 3) Acute/Sub-acute interstitial pneumonia
(including cryptogenic organizing pneumonia and acute interstitial pneumonia). These
groupings are based on clinical, radiological and pathological findings 1.

IPF is a chronic and fatal disease characterized by excessive extracellular matrix (ECM)
protein deposition and a subsequent, and progressive decline in lung function. It has no
known cause and there are limited treatment options that have minimal impact on survival
times for IPF patients 2. The incidence of IPF is increasing and is currently reported to be
about 20 per 100,000 in the USA and Europe 3, 4. The pathogenesis of IPF remains poorly
understood, but it has been proposed that ongoing or repetitive injury to alveolar type II
epithelial cells results in increased apoptosis and the induction of chronic inflammation with
monocytic and lymphocytic infiltration 5. The chronic nature of this response leads to
fibroblast proliferation and myofibroblast differentiation and the excessive deposition and
accumulation of extracellular matrix proteins, predominately type I collagen, within the lung
interstitium 6.

There is a growing appreciation for the role of adaptive immune responses in the initiation
and/or progression of a range of fibrotic diseases. In IPF patients, the presence of lymphoid
aggregates in the lung tissue together with autoantibodies present in the serum, suggest
that the immune system is likely to play a role either in initiation or progression of the
disease. For example, the loss of self-tolerance in auto-reactive T and B cells specific to
antigens derived from damaged or dying lung ECs may drive immune pathology in IPF. In
this review we will provide an overview of how dysregulation of the adaptive immune
response drives chronic inflammation and fibrosis which are hallmarks of IPF.

Characterization of lymphocyte responses in IPF
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IPF has an unknown aetiology but it is characterised by an inflammatory cell infiltrate that
includes neutrophils and mononuclear cells 7, 8. In addition eosinophils and increased
numbers of CD4+ T cells together with raised antibody levels have been reported in the
bronchoalveolar lavage of patients with pulmonary fibrosis8-10. Although these findings
suggest a role for innate and adaptive immunity in the disease process until recently there
have been no clear links made between antigens that may trigger the immune response and
disease pathogenesis. The predominance of T cells in lung tissue and the bronchoalveolar
lavage fluid (BALF) of patients with IPF suggested a role for cell mediated immune responses
in the disease process. However, at the time biomarkers of T cell subsets did not correlate
with disease activity or prognosis 11.

Lymphocyte aggregates in the IPF lung consist of CD3+ T lymphocytes and mature DC cells and
are generally proximate to fibroblastic foci9, 12, 13. A subset of these aggregates also contain
CD20+ B cells which localize in cohesive focal clusters within the centre of the aggregate
resulting in an organized appearance

9, 12, 14

(Figure 1). These tertiary lymphoid structures

(TLSs) have been classified as ectopic lymphoid structures and contain non-proliferating and
non-apoptotic mature CD45RO+ T and B cells evidenced by Ki67 and cleaved caspase 3 staining
9, 12

(Figure 2). This is a unique feature of IPF as pulmonary TLSs present in other diseases such

as chronic obstructive pulmonary disease and idiopathic pulmonary arterial hypertension are
non-proliferative9, 12. Furthermore, TLSs contain mature supporting DCs and large endothelial
cells resembling High Endothelial Venules (HEVs) reminiscent of lymph node organization12.
These inducible TLSs enable B cells to proliferate and differentiate in response to antigen
independently of secondary lymphoid organs12. However, the fact that these TLSs, evident in
IPF lung tissue, contain non-proliferating and non-apoptotic T and B cells suggests another
mechanism is occurring. Despite this, the fact that these TLS are a histological feature of IPF
and absent in the healthy lung suggests that they are an important feature of the disease
pathogenesis.

In an attempt to further characterise the properties of the lymphocyte infiltrate in IPF
patients Herazo –Maya et al examined gene expression arrays using DNA prepared from
peripheral blood mononuclear cells (PBMCs) and they revealed a unique genetic signature
that correlated with disease progression in IPF patients 15. The genetic signature comprised
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four genes that displayed decreased expression levels in IPF patients and these included
Cd28, Icos, Itk and Lck and these markers were confirmed at both the RNA and protein level
15.

Furthermore the signature correlated with a two – four fold increased risk of patients

dying of IPF or having a lung transplant 15. Other genes that were down regulated in IPF
patients were associated with the T cell antigen receptor complex such as CD3, CD3, CD3
suggesting a general downregulation of TCRs and some of these were confirmed by flow
cytometry. This finding was supported independently by Gilani et al. using peripheral blood
CD4+ T cells which also showed decreased CD28 levels on CD4+ T cells of IPF patients and
confirmed that this phenotype correlated with poor survival 16. These findings of modulation
of CD28 expression and predisposition to IPF disease progression in patients are in stark
contrast to results obtained with Cd28-/- mice which are protected from bleomycin-induced
fibrosis 17. Currently it is not understood what causes the decreased expression of Cd28
(and CD3 complex) in IPF patients. Notably all four signature genes are expressed by T cells
but expression of Inducible Costimulator (Icos) is particularly important as it is constitutively
expressed by follicular T helper cells (Tfh) that play a unique role in providing help to B cells
to promote antibody synthesis in germinal centres 18. Other immune biomarkers that also
change in IPF patients include surfactant protein A (SP-A), chemokine ligand 18 (CCL18) and
metalloproteinase 7, intercellular adhesion molecule (ICAM) and interleukin 8 (IL-8) which
have all been found to be highly expressed in PBMCs of IPF patients and correlate with
decreased survival 19-21. Collectively these studies indicate that activation and expansion of T
cells in IPF patients can have an important influence on disease progression and some
specific biomarkers have been identified that can have prognostic value.

The cytokine response of CD4+ T cells has been examined in a number of studies of IPF
patients and consensus indicates an imbalance in the transforming growth factor (TGF)β : IL10 ratio and the presence of high levels of IL-17 in the serum of IPF patients.
Immunostaining of IPF patient lung tissues revealed prominent IL-17 staining in regenerating
epithelial cells 14. The secretion of IL-10 and TGFβ is mediated primarily by CD4+Foxp3+ T
regulatory (Tregs) cells which play a crucial role in immune homeostasis and the
maintenance of self-tolerance 22. In addition Tregs can migrate to non-lymphoid tissues
where they appear to play a crucial role in dampening immune responses at mucosal
surfaces. In addition there is a growing appreciation that Tregs can play important roles
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outside of mucosal tissues like the regulation of metabolic homeostasis in adipose tissue
and can promote repair of skeletal muscle following damage 23-25. Although there is no clear
indication of the fate of Tregs in IPF patients, two studies have observed decreased numbers
of Treg numbers in BALF, blood and in lung tissue 14, 26. In addition, Treg cells from IPF
patients displayed poor suppressive function in vitro 26. In contrast in mouse models of
bleomycin-induced pulmonary fibrosis Tregs can accumulate in large numbers in the lung
tissue and can exacerbate disease through their capacity to secrete TGF. Reilkoff et al.
identified a population of CD4+Sem7a and CD4+Sem7a+ Tregs in peripheral blood that were
expanded in IPF patients, and in mice, the CD4+Sem7a+ Tregs were responsible for disease
progression following bleomycin treatment 27.

A specific lack of Treg cells or a loss in their suppressive activity could have important
implications on the maintenance of self-tolerance in humans and rodents and can lead to
the development of widespread autoimmunity. Naïve CD4+ T cells if activated in the
presence of TGF and IL-10 can differentiate to become inducible CD4+Foxp3+ Tregs (iTregs)
28, 29.

Gagliani et al. demonstrated that CD4+ Th17 cells could transdifferentiate in vivo into

CD4+ Tregs 30, since Foxp3 expression induced in response to TGF signalling could silence
RORt expression which is a nuclear transcription factor required for IL-17 synthesis 31. Due
to plasticity of the CD4+ repertoire the cytokine milieu in which T cells find themselves can
strongly influence their path of differentiation. Recently it was shown that a population of
CD4+IL-17+Foxp3+ Tregs were expanded in the intestinal lamina propria of Crohn’s disease
patients 32. These studies highlight that when CD4+ T cells are exposed for prolonged
periods to cytokines this can impact on their differentiation in vivo. TGF- and IL-6 promote
the differentiation of CD4+ T cells into the Th17 cell lineage in vivo 33, while exposure to IL-10
and TGF- promotes CD4+ Treg differentiation 22. Therefore, the environmental cues within
inflamed tissues may shape the balance of Th17 and Treg cells that arise, but which cell type
dominates during an immune response will be determined by the balance between
inflammatory versus tolerogenic signals 32. A similar scenario may also play out in the lungs
of IPF patients where TGF-, IL-6, IL-17 and IL-10 are detected and it is the manner in which
clonal populations of CD4+ T cells respond to the external cytokine signals emanating from
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damaged epithelial cells or other innate or lymphocyte cell populations that will determine
the outcome of inflammation or immune homeostasis.

Role of B cells in IPF
B cells are the antibody producing cells of the adaptive immune system and follicular B cells
are also capable of responding to two different forms of antigens referred to as (i) Thymus
(T)-independent (TI) or (ii) T-dependent (TD) antigens. TI antigens are associated with
microbial derived products such as cell wall antigens like peptidoglycan, flagellin or
lipopolysaccharide (LPS) or alternatively they may recognize DNA or RNA coming from
microbes such as bacteria and viruses 34. TD antigens are usually directed against exogenous
proteins and these are processed by professional antigen presenting cells such as dendritic
cells to stimulate CD4+ Th cells. The antigen specific Th cell needs to interact with a B cell of
the same antigen specificity and the Th cells provide both cognate and soluble signals to
direct B cells to differentiate into plasma cells that secrete antibody, and a subset of these
cells differentiate into long lasting memory cells 18.TI responses are usually more rapid than
TD responses which is thought to help protect the host from blood borne life threatening
infections and are limited to low affinity IgM responses. In contrast TD antigens can drive
isotype switching and somatic hypermutation of Ig variable genes to increase the affinity of
Abs for their antigen. Studies linking IPF to autoimmunity date back to the early-mid 1960s
with several reports associating idiopathic pulmonary fibrosis with connective tissue
diseases including, rheumatoid arthritis 35, 36. These studies were the first to demonstrate
elevated circulating auto-antibodies in patients with pulmonary fibrosis, albeit with
rheumatism. Large foci of B cell aggregates accumulate in the lung of IPF patients but it is
not known what draws these cells into the lung tissue during disease pathogenesis 12, 37. B
cell aggregates occur in a range of autoimmune diseases such as Systemic Lupus
Erythematosus, Sjogren’s disease, Thyroiditis, type 1 diabetes and rheumatoid arthritis 38-40.
Immune complexes formed between antibody and self-antigen can deposit in tissues to
promote inflammation. In addition antibodies can mediate antibody dependent cellular
cytotoxicity which is mediated via complement activation or via Natural Killer (NK) cell
activity. Immune complexes have been identified in the peripheral blood, BALF and lung
parenchyma of IPF patients 10, 41-43.
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A number of soluble factors that promote B cell growth and differentiation are observed in
the blood of IPF patients including B cell activating factor (BAFF) also known as B
Lymphocyte stimulator (BLyS), IL-6 and IL-13 44. The chemokine CXCL13 is important for
directing migration of B cells to inflammatory foci to promote formation of TLSs. In addition
high levels of CXCL13 have been detected in serum of patients suffering from a range of
autoimmune diseases 45-48. CXCL13 was also demonstrated to be an important biomarker
that was prognostic for IPF disease progression 13. There was increased staining of CXCL13
in the lung of IPF patients and it was also detected in high levels in the plasma of IPF
patients compared to patients with Chronic Obstructive Pulmonary Disease (COPD) 13. To
examine the role of B cells in IPF in a mouse model of pulmonary fibrosis O’Donoghue et al
showed that Rag1-/- mice which lacked both mature T and B cells were protected from
bleomycin induced pulmonary fibrosis 49. Furthermore they showed that simply eliminating
the mature B cell compartment in gp130757F;uMT-/- mice protected them from bleomycininduced gp130/STAT3-mediated lung fibrosis. These studies all support a link between B
cells and the pathogenesis of ILDs such as IPF 49.

IPF as an autoimmune disease
In support of a potential autoimmune role for B cell responses in IPF, serum analysis of autoantibody production in 48 serum samples from patients with IPF 36, reported 32 patients of
48 to have elevated non-organ specific autoantibodies (including rheumatoid factors; DAT
and ANF and Complement fixing antibodies). No lung specific autoantibodies were detected
in this patient cohort. B cell aggregates and the presence of plasma cells in lung tissue of IPF
patients were noted around the same period but their role was largely ignored until more
recent times 11, 50, 51. Numerous studies have highlighted the presence of autoantibodies to
self-antigens in IPF patients suggesting a breakdown in central tolerance in T and B cells to
T-dependent antigens (See Table 1).

B cells can act as professional antigen presenting cells to memory T cells as they can capture
self-antigens and process and present peptide/MHC molecules at the cell surface for
recognition by the TCR on an autoreactive T cell. Several studies have identified that T cells
from IPF patients can demonstrate proliferative responses to lung derived autoantigens
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suggesting a breakdown in T cell tolerance to these tissue specific antigens 16, 26, 43, 52-54.
Feghali- Bostwick et al. demonstrated that CD4+ T cells from IPF patients responded to lung
tissue antigens derived from IPF lung material- but did not respond to protein samples
prepared from lung material of healthy controls [58]. This indicates that the IPF lung must
elaborate self-antigens that have the potential to stimulate self-reactive T cell responses
when presented by antigen presenting cells.

Loss of self–tolerance in IPF
The adaptive T cells of the CD4+ and CD8+ lineages express clonally restricted antigen
specific receptors. These cells are selected in the thymus to express TCRs with low –
moderate affinity for the target antigen 55, 56. Central tolerance in CD4+ and CD8+ T cells is
mediated by antigen presentation via cortical epithelial cells (ECs) in the thymus and is
reinforced by antigen presentation in the medulla by medullary thymic epithelial cells
(mTECs) and bone marrow derived DCs to ensure self-reactive lymphocytes are deleted
within the thymus 57-60.
Studies in mice and humans have revealed the important role for the nuclear transcription
factor Autoimmune Regulator gene, Aire, which confers to a subset of mTECs the capacity
for expression of tissue restricted antigens (TRAs) 61, 62. Aire+ mTECs are able to present a
wide range of self-peptides in association with MHC molecules to induce self-tolerance to
TRAs 61-64. Aire-mediated regulation of TRA expression leads to the translation of the selfproteins which are subsequently processed by the mTECs though the MHCI and MHCII
pathways leading to formation of peptide/MHC (pMHC) complexes which are presented at
the surface of mTECs and these ligands can be scanned by TCRs on thymocytes. If a TCR has
high affinity for the pMHC complex this will lead to clonal deletion of the autoreactive T cell.
Whereas cells with low/medium affinity will be allowed to complete the differentiation and
be exported from the thymus. Autoimmune Polyendocrine Syndrome 1 (APS-1) or
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APCED) is a rare
autosomal recessive monogenic autoimmune disorder caused by mutations in the AIRE gene
65.

The Aire mutation disrupts TRA expression in mTECs leading to loss of central tolerance in

the thymus resulting in the export of autoreactive T cells into the peripheral circulation
which predisposes to autoimmunity 61-64, 66. Recently a second gene called Fezf2 has been
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discovered that can direct the expression of a further subset of TRA genes in a subset of
mTECs that are different to those controlled by Aire 67.
In an effort to provide a molecular basis for the presence of auto-antibodies in patients with
IPF, Alimohammadi et al. identified a subset of APS-1 patients that had evidence of
pulmonary autoimmunity and identified the potassium channel protein, KCNRG as a
putative auto-antigen in these patients 68. In a separate study Shum et al. identified a
human patient with APS-1that developed pulmonary fibrosis and identified vomeromodulin
as a putative auto-antigen 69. Shum also provided evidence that Aire-/- mice develop a
pulmonary disease similar to that observed in APS-1 patients. In a follow up study Shum et
al. identified a strong link between an autoimmune response to the lung-specific protein
BPIFB1 (bactericidal/permeability-increasing fold- containing B1) in APS-1 patients 70. They
found 100% of APS-1 patients with ILD had autoantibodies in the serum to BPIFB1, but it
was also found to be an autoantigen in non APS-1 patients. Furthermore ~15% of patients
with connective tissue disease-associated ILD and 12% of IPF patients displaying autoantibodies to the antigen 70. They found transfer of serum containing BPIFB1
autoantibodies did not confer ILD to recipient mice with an intact immune system, but
transfer of CD4+BPIFB1-specific T cells to Rag1-/- mice developed spontaneous pulmonary
fibrosis and inflammation 70. Furthermore thymic transplant from Aire-/- to
immunodeficient Balb/c nude mice lead to spontaneous development of BPIFB1
autoantibodies in the blood of recipients. Thymic transplants of Aire+/- thymi to nude mice
did not yield any autoantibodies 70. Finally they also showed that immunization of BPIFB1-/mice with the BPIFB1 protein could induce autoantibodies to BPIFB1 and they went onto
develop ILD similar to that observed in Aire-/- mice and IPF patients 70.
Tzouvelekis et al., identified patients with combined pulmonary fibrosis and emphysema
that displayed increased levels of circulating anti-nuclear antibodies (ANAs) in serum and
they had large lymphoid aggregates within lung tissue that consisted of primarily of CD20 + B
cells 71. Thus it appears that chronic pulmonary diseases such as IPF can be associated
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Table 1 Autoantigens identified in Pulmonary fibrosis
Auto antigen

Cellular expression

Function

References

BP1FB1

Synthesized in mucus

Bactericidal & permeability
activity against bacteria

70

Expressed in cells of

Transport function for

69

nasal/olfactory tissue in

pheromones of low volatility

lateral nasal glands, posterior

to gain access to receptors in

septal and vomeronasal

the vomeronasal organ.

production organs e.g. goblet
cells in the nasal cavity and
the upper airways of the
respiratory tract.
Vomeromodulin

glands
Periplakin

Epidermal keratinocyte

A component of desmosomes

72, 73

and epidermal cornified
envelope in keratinocytes
HSP70

Ubiquitous in all cells

Chaperone function in protein

43

folding
KCNRG

Expression in bronchioles

putative potassium channel

68

regulator
Cytokeratin 18

Glandular Epithelial cells

Connects the cell surface to

42

the nucleus
IL-1a

Proinflammatory cytokine

74

Cells in lung bone marrow

Ca2+ dependent phospholipid

75

and intestine

binding proteins

Mesenchymal cells

Involved in cytoskeletal

Macrophages, monocytes,
neutrophils

Annexin 1

Vimentin

76

structure to anchor organelles
in the cytosol
Collagen V

Lung interstitium

Barrier function of basement

77

membrane
Cytokeratin 8, 18
and 19

Alveolar type II cells, Broncho

Filaments associated with the

epithelial cells

cytoskeleton of epithelial cells

42, 78, 79
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with a breakdown in immune tolerance and generation of autoimmunity. Table 1 provides a
summary of the known autoantigens that have been described in IPF patients and those
antigens highlighted in bold have been shown to be present in APS-1 patients linking it to a
defect in central tolerance mediated by AIRE.

Conclusion:
In the last 20 years immunologists have gained greater insight into the links between the
innate and adaptive immune response generated not only to pathogens but also to selfantigens in the context of autoimmunity. Susceptibility to IPF is likely to have requirements
of genetic and environmental components. Genome wide association studies have
identified some key target genes and a number of these have been associated with cellular
function of epithelial cells in the airways. Defects in signalling pathways that are crucial to
clearing cellular debris may facilitate autoantibody formation and this may tip the scales
toward disease pathogenesis. A failure to appropriately regulate the adaptive immune
response could be detrimental to the host and predispose to chronic inflammation and
damage and tissue remodelling with deposition of collagen leading to fibrotic disease. Th
cell differentiation is directed by the presence of cytokines and the balance between
proinflammatory or immune regulatory cytokines during the period of damage to lung
epithelial cells which could favour development of autoimmunity.

The recent discovery of the role of Aire and predisposition to pulmonary fibrosis in both
mice and humans provides a new and exciting breakthrough in providing a molecular
mechanism to explain the breakdown in immune tolerance to lung derived self-antigens.
Although Aire mutations may only be present in a subset of IPF patients it does provide an
avenue to understand how a breakdown in T cell tolerance may occur and how the
autoreactive T and B cells may be inappropriately activated. Perhaps there are other Airelike genes such as Fezf2, that direct TRA expression in the thymus that await to be
discovered. Mutations in genes that direct promiscuous expression of TRAs in thymic
mTECs could explain the diversity of target autoantigens that have been defined to date in
IPF patients. Once the initial priming event has occurred this can lead to formation of
memory T and B cells specific for the target autoantigens. Because of the altered
costimulatory requirements of memory cells this can prove more challenging in trying to
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dampen immune responses to self-antigens. Nevertheless scientists have made some
significant advances in the understanding the process of disease pathogenesis in IPF.
Although we may still be some distance away from understanding the full pathogenesis of
the disease it has revealed some important insights that provide potential targets for
immunotherapy in the future.

Future studies may need to focus on how the innate and adaptive immune responses in IPF
unfold. There have been significant breakthroughs in our understanding of the diversity of
innate cellular repertoire that helps to maintain immune homeostasis in mucosal sites. The
innate immune cells play a critical role in directing epithelial cell repair and maintaining the
barrier function of the epithelium. The next decade should be able to provide a fertile area
of research as the genetic tools for studying disease pathogenesis are being developed and
provide a valuable resource to understand how dysregulation of the immune system occurs.
Although the mouse models of IPF may not accurately reflect on the inflammatory response
in IPF patients, they will still prove valuable to help scientists dissect the cellular and
molecular regulation of immune response in what is a complex disease.
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Figure 1. Accumulation of CD20+ B cell aggregates in the lung tissue of IPF patients around
areas of pulmonary fibrosis that are normally absent in healthy lungs. A. Masson’s trichrome
stain of the lung tissue of an IPF patient. B. Immunohistochemical stain of CD20 + B cells in a
serial section of the same tissue. The CD20+ aggregates accumulate in areas where there is
fibrosis (blue areas in A).

Figure 2. Model of disease pathogenesis of IPF due to breakdown in self-tolerance to lung
specific protein antigens. A. In the thymus AIRE+ mTECs can present self-antigens to
developing thymocytes and self-reactive T cells are eliminated by apoptosis. In patients with
APS-1 with mutations in which the Aire gene is faulty- mTECs fail to eliminate lung –specific
T cells and they complete maturation in the thymus and migrate to the periphery. B. In
response to injury in the lung, dendritic cells (DCs) can pick up and process lung specific Ag
and migrate to regional lymph nodes or spleen to present Ag to lung-specific Th cells. C. The
activated Th cells can provide help to Ag-specific B cells and both undergo clonal expansion.
Ag-specific B cells can mature as plasma cells and secrete auto-Abs into the blood. D.
Autoreactive T and B cells migrate to the lung to form tertiary lymphoid structures (TLs) but
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they typically lack proliferating B cells and apoptotic cells in these sites which are hallmarks
of active germinal centres 9, 12, 44. Due to chronic tissue damage fibrosis develops and leads
to IPF pathogenesis.

